文献速递眼底病与葡萄膜炎

Müller胶质细胞是AMD神经保护与再生的守门人?病理生理与治疗创新中的角色

Are Müller glial cells gatekeepers of neuroprotection and regeneration in age-related macular degeneration? Unraveling their roles in pathophysiology and therapeutic innovation.
PubMed 文献 · Prog Retin Eye Res · 2026-04-14

本文综述提出以Müller胶质细胞为中心的AMD进展框架,整合细胞稳态、结构转变与阶段依赖性治疗意义。早期AMD中Müller细胞呈适应反应,基底膜沉积累积与外界膜(ELM)下移标志不可逆退变临界点;ELM前阶段适合神经保护与代谢干预,ELM后阶段需稳定与限制退变策略。

要点

  • Müller胶质细胞主动参与AMD病理,包括补体调节、代谢耦联、氧化还原控制与炎症信号。
  • 外界膜(ELM)下移是Müller细胞支持丧失与不可逆退变的关键转折。
  • 现有临床试验多未纳入Müller细胞状态或ELM完整性作为分层变量。

核心结论

  • Müller胶质细胞可能是AMD视网膜稳态与疾病进展的核心整合者,整合胶质生物学与结构生物标志物有望实现阶段特异性精准治疗并改进临床试验设计。

研究设计与样本

  • 本文为综述,整合转录组学、组织学与功能证据,提出以Müller胶质细胞为中心的AMD进展框架。

主要发现

  • 早期AMD中Müller胶质细胞呈适应反应,在代谢与细胞外应激增加时仍维持视网膜完整性。
  • 基底膜沉积累积与细胞外重塑可能造成扩散受限与炎症负担,促进胶质重编程。
  • 外界膜(ELM)下移对应光感受器支持丧失、视网膜区室化破坏与不可逆退变开始。
  • ELM下移后Müller胶质细胞发生结构重塑并参与视网膜下胶质膜形成,由稳态支持转向包裹限制。

关键数值与推荐

  • ELM前阶段以保留可塑性为特征,适合神经保护与代谢干预。
  • ELM后阶段需聚焦稳定与限制退变的策略。
  • 多数当前临床试验未明确将Müller胶质细胞状态或ELM完整性作为分层变量。

临床怎么用

  • 临床可关注ELM完整性作为AMD阶段分层与治疗窗口判断的结构生物标志物。
  • ELM前阶段可考虑神经保护与代谢干预思路,ELM后阶段以稳定与限制退变为重点。

局限性

  • 本文为综述,未报告原始研究样本量、效应量或P值等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Age-related macular degeneration (AMD) is traditionally conceptualized as a disorder of the retinal pigment epithelium (RPE)-photoreceptor axis; however, this paradigm incompletely explains early disease dynamics and therapeutic failure in geographic atrophy (GA). This review aims to reframe AMD progression through a Müller glial cell-centered framework that integrates cellular homeostasis, structural transitions, and stage-dependent therapeutic implications. Emerging transcriptomic, histologic, and functional evidence demonstrates that Müller glial cells actively participate in AMD pathobiology, including complement regulation, metabolic coupling, redox control, and inflammatory signaling. In early AMD, Müller glial cells exhibit adaptive responses that preserve retinal integrity despite increasing metabolic and extracellular stress. Progressive accumulation of basal laminar deposits and extracellular remodeling may impose diffusion constraints and inflammatory burden, thereby promoting glial reprogramming. A critical transition occurs with descent of the external limiting membrane (ELM), which corresponds to the loss of photoreceptor support, disruption of retinal compartmentalization, and onset of irreversible degeneration. Beyond this threshold, Müller glial cells undergo structural remodeling and contribute to the formation of subretinal glial membranes, reflecting a shift from homeostatic support to containment. This framework proposes a biologically testable staging axis from preserved Müller glial cell function to progressive dysfunction, aligning disease progression with therapeutic windows. Pre-ELM stages are characterized by retained plasticity and suitability for neuroprotective and metabolic interventions, whereas post-ELM stages require strategies focused on stabilization and limiting degeneration. Importantly, most current clinical trials do not explicitly incorporate Müller glial cell state or ELM integrity as stratification variables, potentially contributing to insensitive or diluted outcome assessment. In conclusion, Müller glial cells may function as central integrators of retinal homeostasis and disease progression in AMD. Integrating glial biology with structural biomarkers may enable stage-specific precision therapies and improve clinical trial design.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Chen KY, Chan HC, Hwang YS, et al. Are Müller glial cells gatekeepers of neuroprotection and regeneration in age-related macular degeneration? Unraveling their roles in pathophysiology and therapeutic innovation. Prog Retin Eye Res. 2026. PMID: 41985834. doi:10.1016/j.preteyeres.2026.101471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。